A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Sonrotoclax (Primary) ; Zanubrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors BeOne Medicines
Most Recent Events
- 28 Nov 2024 Status changed from not yet recruiting to recruiting.
- 17 Oct 2024 New trial record